Table 3. Hazard ratios (HR) and 95% confidence intervals (95% CI) ) for all cancer and specific cancers by baseline or updated mean HbA1c at Cox regression, in people with and type 2 diabetes followed for 12 years from 1997–99 to 2009.

	Baseline HbA1c	Baseline HbA1c (mmol/mol)				Updated mean HbA1c (mmol/mol)
	Per 1%	≤58	>58			≤58	>58
	increase		Model 1	Model 2	Model 3		Model 1	Model 2	Model 3
	HR (95% CI)		HR (95% CI)				HR (95% CI)
All cancer	1.01(0.98–1.04)	Ref	0.99(0.92–1.06)	1.02(0.95–1.10)	1.02(0.95–1.09)	Ref	1.01(0.95–1.08)	1.04(0.97–1.12)	1.03(0.96–1.10)
Gastrointestinalcancer	1.00(0.94–1.06)	Ref	0.98(0.86–1.12)	1.03(0.89–1.20)	1.02(0.88–1.18)	Ref	1.02(0.89–1.17)	1.12(0.97–1.29)	1.09(0.94–1.26)
Kidney andurinary cancer	1.00(0.94–1.06)	Ref	0.86(0.56–1.32)	0.86(0.55–1.36)	0.87(0.55–1.37)	Ref	0.71(0.46–1.09)	0.70(0.44–1.10)	0.70(0.44–1.10)
Respiratorycancer	1.00(0.85–1.19)	Ref	0.87(0.57–1.32)	0.83(0.53–1.31)	0.84(0.53–1.32)	Ref	0.99(0.65–1.52)	1.00(0.64–1.57)	1.00(0.63–1.56)
Female genitalcancer	1.00(0.89–1.12)	Ref	1.06(0.79–1.41)	1.03(0.75–1.41)	1.06(0.77–1.46)	Ref	1.17(0.88–1.57)	1.18(0.86–1.61)	1.22(0.89–1.68)
Breast cancer	1.01(0.92–1.10)	Ref	1.08(0.87–1.36)	1.08(0.85–1.38)	1.09(0.86–1.39)	Ref	1.10(0.88–1.38)	1.12(0.88–1.43)	1.12(0.88–1.43)
Prostate cancer	1.00(0.94–1.06)	Ref	0.97(0.84–1.12)	1.04(0.89–1.21)	1.05(0.90–1.22)	Ref	0.92(0.80–1.07)	0.98(0.84–1.14)	0.96(0.82–1.11)

Model 1: Crude HR, without adjustment for covariates. Model 2: Adjustment for age, sex, diabetes duration, BMI, smoking, and insulin treatment as covariates. Model 3: Adjusted HR after stratification with a propensity score. Adjustment by stratification with quintiles of a propensity score including covariates as in Model 2.